Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2013. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of October 31, 2013, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
| Capital Metric | Value as of Oct 31, 2013 |
|---|---|
| Total Issued Ordinary Shares (25p each) | 5,370,291,464 |
| Treasury Shares | 507,894,912 |
| Total Voting Rights | 4,862,396,552 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document focuses solely on the current capital structure snapshot.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,862,396,552) to determine notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (507,894,912) when calculating outstanding share counts.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.